Lilly to seek FDA approval for potential Alzheimer’s drug

INDIANAPOLIS (AP) — Eli Lilly says it will submit its potential Alzheimer’s treatment to federal regulators later this year. The announcement comes a few weeks after the Food and Drug Administration approved a treatment from rival Biogen despite warnings from the agency’s independent advisers that it hasn’t been shown to help slow the brain-destroying disease.  Lilly said Thursday that it will seek approval for its potential treatment, donanemab, based on data from a mid-stage clinical study of the drug involving 272 patients. Company shares rose around 7% in pre-market trading.